Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for EIK1001 in Advanced melanoma. The expected timing is based on the latest available company guidance and may change.
05/11/26:- TeLuRide-006 Ph2/3 ongoing in 1L advanced melanoma; first interim analysis expected H2 2026. 07/27/26:- TeLuRide-006 (NCT06697301) Ph2/3 enrolling; initiated May 2025. 08/11/26:- DMC selected 0.60 mg/m2 dose for TeLuRide-006; study continues as planned. 08/13/26:- TeLuRide-006 first interim analysis and dose selection were reiterated; the study will continue as planned.
Verification
Confirm timing and program details against the company announcement or filing.